Anaptys soars as skin disease treatment succeeds in late-stage study

AnaptysBio

09/10/2023 13:44

** Shares of drug developer AnaptysBio  ANAB.O  jump 23.4%
to $23.78 premarket
    ** Co says its skin disease drug, imsidolimab, met the main
goal in a late-stage study
    ** The drug helped in clearing pus-filled blisters in
patients suffering with generalized pustular psoriasis (GPP) in
four weeks
    ** GPP is a rare skin disease in which pus-filled blisters
often cover large areas of the body and typically cause fever,
shivers, intense itching and joint pain
    ** Up to last close, shares down 37.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))